Program
fulipiftide
Also written as “BRM421”, “BRM421 Ophthalmic Solution, 0.03%” and “BRM421 Ophthalmic Solution, 0.06%”.
Its studies are mostly in Dry Eye Syndromes · Keratoconjunctivitis Sicca · Keratitis, led by BRIM Biotechnology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BRIM Biotechnology | 52 open or running | phase 3since Apr 9, 2020 | Feb 23, 2017 | Nov 2026phase 2 · NCT07078955 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2017First study: phase 2 study in Dry Eye SyndromesFirst studyNCT03066219 · 157 enrolled · United States
- Apr 9, 2020Phase 3 study in Dry Eye SyndromesNCT04343287 · 220 enrolled · United States
- Jan 13, 2023Phase 3 study in Dry Eye SyndromesNCT05695781 · 740 enrolled · United States
- May 31, 2023Phase 2 study in Neurotrophic KeratitisNCT05927428 · 12 planned · United States
- Jul 14, 2025Phase 2 study in Dry Eye SyndromesNCT07078955 · 99 planned · Taiwan
Ahead
- Nov 2026Primary completion: phase 2 study in Dry Eye SyndromesNCT07078955
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07078955Dry Eye Syndromes · Taiwan | 2 | Not yet recruiting | Nov 2026 | 99 |
| NCT05927428Neurotrophic Keratitis · United States | 2 | Recruiting | Aug 30, 2025 | 12 |
| NCT05695781Dry Eye Syndromes · United States | 3 | Completed | Dec 30, 2023 | 740 |
| NCT04343287Dry Eye Syndromes · United States | 3 | Completed | Jun 23, 2020 | 220 |
| NCT03066219Dry Eye Syndromes · United States | 2 | Completed | May 20, 2017 | 157 |
How it is read
Names in the registry
- “BRM421”, 2 entries
- “BRM421 Ophthalmic Solution, 0.03%”, 1 entry
- “BRM421 Ophthalmic Solution, 0.06%”, 1 entry
- “BRM424 Ophthalmic Solution - Dose1”, 1 entry
- “BRM424 Ophthalmic Solution - Dose2”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 3 studies
- Keratoconjunctivitis Sicca, 1 study
- Keratitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.